65,437 trials
Acute Myocardial Infarction
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants
Cystic Fibrosis
Primary: Parts A, B and C: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 0; 3; 1; 2 Participants
Neuroendocrine Tumors · Carcinoid Tumors
Primary: Progression-free Survival (PFS) at One Year — 11 months
Epilepsy
Primary: Number of Participants With At Least One Treatment-Emergent Adverse Event (TEAE) — 336 Participants
Cerebral Palsy
Primary: Change in Manual Dexterity — 10.7; 12.4; 14.4 points on assessment — p=0.03
End Stage Renal Disease
Primary: Time for Complete Infusion of 4.5 mL Triferic AVNU Pre-Dialyzer — 1.7 hours
Breast Cancer
Primary: Hematological - Dose Limiting Toxicities — 1; 3; 7; 1 participants
Osteoarthritis, Knee
Primary: Overall Reliability of Monitoring Technology, Measured as Proportion of Actual Data Received From the Patient's Home Compared to the Amount of Data Expected (Based on…
Carotid Artery Stenosis
Primary: Evidence of Injury to the Artery or Cerebral Ischemia Secondary to Shunt Placement and Removal — 3 Participants
Breast Cancer
Primary: Demonstration of the Feasibility and Safety of Delivering a Radiation Treatment Using the GammaPod (TM) — 14 Participants
Ulcerative Colitis
Primary: Number of Participants With Remission Based on Composite Score at Week 52 — 6; 38; 11; 33 Participants — p=<0.001
Catheter Infection · Catheter Thrombosis · Catheter Complications
Primary: Upper Extremity CR-UEVT — 7; 11 Participants
Head and Neck Cancer
Primary: 1-year Local Control — NA; NA months
Degenerative Disc Disease · Trauma (Including Fractures) · Spondylolisthesis
Primary: Radiological Assessment : Fusion Status — 20 participants
Conscious Sedation
Primary: Number of Participants Compliant With Oral or Nasal Midazolam Administration — 11; 4; 14; 18 Participants